CD8+ and CD4+ T lymphocytes can be activated directly or indirectly by cancer cells: in the first case, tumour cells can present neoantigens by means of MHC-I and MHC-II molecules; alternatively, T cell activation can occur indirectly through dendritic cells (DC) or macrophages (M), killing, processing and presenting neoantigens to T lymphocytes [12]. Here, CD8A is linked to cancer.